<- Go Home
Soleno Therapeutics, Inc.
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
Market Cap
$2.8B
Volume
1.6M
Cash and Equivalents
$133.0M
EBITDA
$91.5M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$281.1M
Profit Margin
98.63%
52 Week High
$90.32
52 Week Low
$29.43
Dividend
N/A
Price / Book Value
5.52
Price / Earnings
29.97
Price / Tangible Book Value
5.57
Enterprise Value
$2.3B
Enterprise Value / EBITDA
24.71
Operating Income
$89.5M
Return on Equity
26.38%
Return on Assets
12.07
Cash and Short Term Investments
$255.6M
Debt
$54.3M
Equity
$495.8M
Revenue
$285.0M
Unlevered FCF
$95.0M
Sector
Biotechnology
Category
N/A